Thrombolysis for acute stroke

Purpose of reviewStroke thrombolysis is in the process of moving from academic centers into community-based standard therapy in experienced centers. Recently published data on patient selection, imaging and other technical or organizational advances are reviewed in order to improve the safety and efficacy of stroke thrombolysis and identify areas in which more study is needed. Recent findingsDuring the past year, several open series were published on the application of thrombolysis in community-based settings, which have mostly reproduced the outcome described in randomized, placebo-controlled recombinant tissue plasminogen activator cohorts. New information has been produced to identify the clinical parameters that are associated with good and adverse outcomes after stroke thrombolysis. Elevated blood glucose decreases the likelihood of a good outcome and increases that of cerebral hemorrhagic change, but the effect of early glucose reduction needs to be investigated. Non-contrast computed tomography still prevails as the standard imaging method in patient selection, but computed tomography angiography can be added within a reasonable time to furnish vascular diagnosis. Perfusion-weighted imaging is used to quantify the fraction of brain tissue salvaged by intravenous thrombolysis, and may be used in the future to select patients with still viable penumbral brain tissue, even beyond a 3-h time-window, if efficacy can be proved. SummaryThrombolysis with recombinant tissue plasminogen activator is well tolerated and effective within 3 h of symptoms, and new trials will determine if extension of this time-window or new target populations for thrombolysis, such as children with stroke, can be substantiated. An unfinished task remains in the education of health personnel; imperatives stemming from pathophysiology need to penetrate attitudes on acute stroke at all levels before acute therapies such as thrombolysis can have an impact on stroke outcome in general.

[1]  Alan D. Lopez,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. , 2002, The New England journal of medicine.

[2]  J. Broderick,et al.  Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial , 2002, Neurology.

[3]  Lalit Kalra,et al.  A multicentre observational study of presentation and early assessment of acute stroke , 2002, BMJ : British Medical Journal.

[4]  Karen Smith,et al.  Treatment of Comatose Survivors of Out-of-hospital Cardiac Arrest With Induced Hypothermia , 2003 .

[5]  Marc Fisher,et al.  Thrombolytic Therapy Within 3 to 6 Hours After Onset of Ischemic Stroke: Useful or Harmful? , 2002, Stroke.

[6]  Andrew M. Demchuk,et al.  Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical Practice: The Multicenter rt-PA Acute Stroke Survey , 2002, Circulation.

[7]  P. Vespa,et al.  Predictors of Hemorrhagic Transformation in Patients Receiving Intra-Arterial Thrombolysis , 2002, Stroke.

[8]  Michael Holzer,et al.  Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest , 2002 .

[9]  S. Bernard,et al.  Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. , 2002, The New England journal of medicine.

[10]  J. Schulte‐Mönting,et al.  Hyperglycemia in Patients with Focal Cerebral Ischemia after Intravenous Thrombolysis: Influence on Clinical Outcome and Infarct Size , 2002, Cerebrovascular Diseases.

[11]  J. Sunshine,et al.  Endovascular Administration after Intravenous Infusion of Thrombolytic Agents for the Treatment of Patients with Acute Ischemic Strokes , 2002, Neurosurgery.

[12]  V. Larrue,et al.  High Rate of Recanalization of Middle Cerebral Artery Occlusion During 2-MHz Transcranial Color-Coded Doppler Continuous Monitoring Without Thrombolytic Drug , 2002, Stroke.

[13]  Stephen Rose,et al.  Diffusion‐ and perfusion‐weighted MRI response to thrombolysis in stroke , 2002, Annals of neurology.

[14]  V. Hachinski,et al.  Extending Tissue Plasminogen Activator Use to Community and Rural Stroke Patients , 2002, Stroke.

[15]  J. Grotta,et al.  Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. , 2001, JAMA.

[16]  J. Arenillas,et al.  Time Course of Tissue Plasminogen Activator–Induced Recanalization in Acute Cardioembolic Stroke: A Case-Control Study , 2001, Stroke.

[17]  A. Alexandrov,et al.  Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. , 2001, Archives of neurology.

[18]  B. McCrindle,et al.  Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. , 2001, The Journal of pediatrics.

[19]  S. Schwab,et al.  Endovascular Cooling for Moderate Hypothermia in Patients With Acute Stroke: First Results of a Novel Approach , 2001, Stroke.

[20]  A. Buchan,et al.  Thrombolysis must be considered after stroke , 2001, BMJ : British Medical Journal.

[21]  J. Noth,et al.  Long-Term Follow-Up of Patients after Intraarterial Thrombolytic Therapy of Acute Vertebrobasilar Artery Occlusion , 2001, Cerebrovascular Diseases.

[22]  J. Wardlaw Overview of Cochrane thrombolysis meta-analysis , 2001, Neurology.

[23]  Christopher Putman,et al.  Utility of Perfusion-Weighted CT Imaging in Acute Middle Cerebral Artery Stroke Treated With Intra-Arterial Thrombolysis:: Prediction of Final Infarct Volume and Clinical Outcome , 2001, Stroke.

[24]  D. Tanné,et al.  Predictors of good outcome after intravenous tPA for acute ischemic stroke , 2001, Neurology.

[25]  F. Buonanno,et al.  CT Angiography in the Rapid Triage of Patients with Hyperacute Stroke to Intraarterial Thrombolysis: Accuracy in the Detection of Large Vessel Thrombus , 2001, Journal of computer assisted tomography.

[26]  H. Diener,et al.  Imaging in cerebrovascular disease , 2001, Current opinion in neurology.

[27]  Erich Bluhmki,et al.  Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.

[28]  Gary Duckwiler,et al.  Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging , 2000, Annals of neurology.

[29]  R. Higashida,et al.  Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial , 1999 .

[30]  G. Albers,et al.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. , 1999, JAMA.

[31]  S. Morikawa,et al.  Effects of blood sugar level on rat transient focal brain ischemia consecutively observed by diffusion‐weighted EPI and 1H echo planar spectroscopic imaging , 1999, Magnetic resonance in medicine.

[32]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[33]  W D Heiss,et al.  Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. , 1998, Stroke.

[34]  F. Van de Werf,et al.  Thrombolysis for acute myocardial infarction. , 1998, Circulation.

[35]  L Bozzao,et al.  Acute stroke: usefulness of early CT findings before thrombolytic therapy. , 1997, Radiology.

[36]  Eric Boersma,et al.  Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour , 1996, The Lancet.

[37]  P D Lyden,et al.  Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. , 1996, Circulation.

[38]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[39]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[40]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.

[41]  M. Hennerici,et al.  Imaging in cerebrovascular disease. , 1992, Current Opinion in Neurology and Neurosurgery.

[42]  J. Lyons,et al.  Thrombolysis for myocardial infarction. , 1986, British journal of hospital medicine.